Builds on recent FDA approval (May 29, 2026) of Afrezza for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes New data and real-world findings further emphasize...
Phase 1b INFLO-1 study data readout anticipated in Q3 2026 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a biopharmaceutical...
MannKind (NASDAQ:MNKD) said the U.S. Food and Drug Administration has approved Afrezza for pediatric patients with diabetes ages 6 and older, expanding the inhaled mealtime insulin’s label into children...
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that management will host a conference call to discuss the recent FDA...
Enables dosing at the start of a meal, offering flexibility for children and adolescents as they manage school, sports, meals, and snacks throughout the day Approval advances pediatric diabetes care...
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , announced today that Chief Executive Officer, Michael Castagna, PharmD will participate...
New analyses examine Afrezza across pediatric A1c and efficacy, patient treatment satisfaction, use with AID algorithms and investigator-led research in pregnancy Late-breaking comparative data vs....
Q1 updates: Q1 2026 total revenues of $90.2M, +15% vs. Q1 2025 Built out launch infrastructure and aligned field-based teams for upcoming launches Settlement of senior convertible notes of $36.3M...
The formulation is being developed in collaboration with United Therapeutics Corporation United Therapeutics made an additional $5 million payment to MannKind to support the rapid advancement of ralinepag...